E-viri
-
Büchner, T; Hiddemann, W; Urbanitz, D; Kreutzmann, H; Maschmeyer, G; Wendt, F; Kuse, R; Mohr, A; Gassmann, W; Löffler, H
Haematology and blood transfusion, 1987, Letnik: 30Journal Article
Major chemotherapeutic alternatives for AML have been implemented and compared in three multicenter studies, including a total of 877 adult patients of all ages. The results strongly suggest that myelosuppressive postinduction treatment is a prerequisite for the achievement of long-term remissions. In addition, it was possible to establish an important antileukemic effect of monthly maintenance chemotherapy. Initial results from an intensive two-course preremission therapy concept revealed good practicability and acceptable toxicity, as well as promising response and remission durations by this new approach.
